Resumen de acción ME
23andMe Holding Co. opera como empresa de pruebas genéticas para consumidores.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de 23andMe Holding Co.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$2.21 |
| 52 Week Low | US$0.35 |
| Beta | 1.28 |
| 1 Month Change | -2.66% |
| 3 Month Change | -27.59% |
| 1 Year Change | -76.19% |
| 3 Year Change | -94.96% |
| 5 Year Change | n/a |
| Change since IPO | -94.87% |
Noticias y actualizaciones recientes
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02Recent updates
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate
Jul 1323andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected
Jun 1523andMe: Disappointing Results Could Mean Potential Acquisition Target
Sep 2723andMe: Treacherous Path To Profitability
Aug 2623andMe drops 8% as CFO resigns
Aug 1923andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target
Aug 1123andMe Q1 2023 Earnings Preview
Aug 0723andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
Jun 1523andMe: A Genetics Innovator Positioned For Growth
Feb 19Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues
Feb 1823andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive
Nov 2123andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains
Oct 03Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth
Sep 1723andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding
Jul 19Rentabilidad de los accionistas
| ME | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 8.2% | -2.3% | 0.7% |
| 1Y | -76.2% | -0.01% | 23.9% |
Rentabilidad vs. Industria: ME obtuvo unos resultados inferiores a los del sector US Healthcare , que el año pasado arrojó un rendimiento del 1%.
Rentabilidad vs. Mercado: ME underperformed the US Market which returned 24.2% over the past year.
Volatilidad de los precios
| ME volatility | |
|---|---|
| ME Average Weekly Movement | 19.1% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ME's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: ME's weekly volatility has increased from 14% to 19% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 758 | Anne Wojcicki | www.23andme.com |
23andMe Holding Co. opera como empresa de pruebas genéticas para consumidores. La empresa opera en dos segmentos, Consumer & Research Services y Therapeutics. El segmento de Servicios de Consumo e Investigación ofrece un conjunto de informes genéticos, incluida información sobre los orígenes genéticos ancestrales de los clientes, los riesgos genéticos personales para la salud y las posibilidades de transmitir a sus hijos determinadas enfermedades raras, así como informes sobre cómo la genética puede influir en la respuesta a los medicamentos.
Resumen de fundamentos de 23andMe Holding Co.
| Estadísticas fundamentales de ME | |
|---|---|
| Capitalización bursátil | US$243.68m |
| Beneficios(TTM) | -US$521.97m |
| Ingresos (TTM) | US$247.99m |
1.0x
Ratio precio-ventas (PS)-0.5x
Ratio precio-beneficio (PE)¿Está ME sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ME | |
|---|---|
| Ingresos | US$247.99m |
| Coste de los ingresos | US$135.66m |
| Beneficio bruto | US$112.33m |
| Otros gastos | US$634.30m |
| Beneficios | -US$521.97m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.08 |
| Margen bruto | 45.30% |
| Margen de beneficio neto | -210.48% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ME a largo plazo?
Ver rendimiento histórico y comparativa